Application and Prospect of Platelet Multi-omics Technology in Study of Blood Stasis Syndrome

Ying LI; Ming-qian SUN; Lei LI; Ye-hao ZHANG; Lan MIAO; Jian-xun LIU

doi:10.1007/s11655-021-3349-y

Your Location：

Home >

Browse articles >

Application and Prospect of Platelet Multi-omics Technology in Study of Blood Stasis Syndrome

Perspective | Updated：2022-02-22

- Application and Prospect of Platelet Multi-omics Technology in Study of Blood Stasis Syndrome
- Application and Prospect of Platelet Multi-omics Technology in Study of Blood Stasis Syndrome
- Chinese Journal of Integrative Medicine 2022年28卷第2期页码：99-105
- Affiliations：
  
  Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Chinese Medicine Cardiology, Beijing (100091), China
- Author bio：
  
  Dr. LIU Jian-xun, E-mail: liujx0324@sina.com
- Funds：
  
  the National Natural Science Foundation of China(82030124);Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(ZYYCXTD-C-202007)
- DOI：10.1007/s11655-021-3349-y
  中图分类号：
- 纸质出版日期：2022-02-01，
  
  网络出版日期：2021-12-20，
  
  录用日期：2021-10-13
Scan for full text
Ying LI, Ming-qian SUN, Lei LI, 等. Application and Prospect of Platelet Multi-omics Technology in Study of Blood Stasis Syndrome[J]. Chinese Journal of Integrative Medicine, 2022,28(2):99-105.

Ying LI, Ming-qian SUN, Lei LI, et al. Application and Prospect of Platelet Multi-omics Technology in Study of Blood Stasis Syndrome[J]. Chinese Journal of Integrative Medicine, 2022,28(2):99-105.
Ying LI, Ming-qian SUN, Lei LI, 等. Application and Prospect of Platelet Multi-omics Technology in Study of Blood Stasis Syndrome[J]. Chinese Journal of Integrative Medicine, 2022,28(2):99-105. DOI： 10.1007/s11655-021-3349-y.

Ying LI, Ming-qian SUN, Lei LI, et al. Application and Prospect of Platelet Multi-omics Technology in Study of Blood Stasis Syndrome[J]. Chinese Journal of Integrative Medicine, 2022,28(2):99-105. DOI： 10.1007/s11655-021-3349-y.

摘要

血小板的功能异常在血瘀证的发病与演化中发挥着重要作用

对其机理的阐释是研究心脑血管疾病及治疗方案的关键科学问题. 不断发展的系统生物学技术为深入开展血小板多组学提供了良好的技术平台

从而有利于对血瘀证生物学机理的科学阐释. 本文总结了血小板在血瘀证中的发病机制

活血化瘀药的作用机制与转录组学、蛋白组学、代谢组学在血小板研究中的应用

本团队从病证结合研究的角度首次提出 "血瘀证血小板组学" 的概念

拟通过多组学技术和系统生物学交互验证

以心脑血管病的临床和基础研究为主

围绕血小板功能及分泌系统

系统阐释血瘀证形成与发展过程中的血小板活化、聚集、释放等不同阶段的分子生物学机制

对阐明血瘀证的发病机制与活血化瘀药的作用机理提供了一种新的研究思路与方法.

Abstract

The abnormality of platelet function plays an important role in the pathogenesis and evolution of blood stasis syndrome (BSS). The explanation of its mechanism is a key scientific issue in the study of cardiovascular and cerebrovascular diseases and treatment. System biology technology provides a good technical platform for further development of platelet multi-omics

which is conducive to the scientific interpretation of the biological mechanism of BSS. The article summarized the pathogenesis of platelets in BSS

the mechanism of action of blood activating and stasis resolving drugs

and the application of genomics

proteomics

and metabonomics in platelet research

and put forward the concept of "plateletomics in BSS". Through the combination and cross-validation of multi-omics technology

it mainly focuses on the clinical and basic research of cardiovascular and cerebrovascular diseases; through the interactive verification of multiomics technology and system biology

it mainly focuses on the platelet function and secretion system. The article systematically explains the molecular biological mechanism of platelet activation

aggregation

release

and other stages in the formation and development of BSS

and provides a new research idea and method for clarifying the pathogenesis of BSS and the mechanism of action of blood activating and stasis resolving drugs.

关键词

Keywords

blood stasis syndromeplatelettranscriptomicsmetabonomicsproteomics

references

Xu H, Chen KJ. Practical diagnostic criterion of blood stasis syndrome: Activating Blood Circulation Committee of Chinese Association of Integrative Medicine. Chin J Integr Med 2017;23:243-244.

Li XF, Jiang YR, Wu CF, et al. Correlation between platelet functional protein and syndrome of coronary heart disease.Chin J Molecular Cardiol (Chin) 2009;9:326-331.

Pinedo HM, Verheul HM, Damato RJ, et al. Involvement of platelets in tumour angiogenesis? Lancet 1998;352:1775-1777.

He LW, Fan FT, Hou XB, et al. Resveratrol suppresses pulmonary tumor metastasis by inhibiting platelet-mediated an-giogenic responses. J Surg Res 2017;217:113-122.

Ruger BM, Buchacher T, Dauber EM, et al. De novo vessel formation through cross-talk of blood-derived cells and mesenchymal stromal cells in the absence of pre-existing vascular structures. Front Bioeng Biotechnol 2020;8:602210.

Quan L, Jing YF, Jing YH. Chinese herbal remedies affecting thrombosis and hemostasis: a review. World J Tradit Chin Med (Chin) 2015;1:38-49.

Wu D, Kanda A, Liu Y, et al. Involvement of müller glial autoinduction of TGF-β in diabetic fibrovascular proliferation via glial-mesenchymal transition. Invest Ophthalmol Vis Sci 2020;61:1-13.

Tsujl TK, Sato M, Fujita M, et al. The role of PI3K/Akt/mTOR signaling in dose dependent biphasic effects of glycine on vascular development. Biochem Biophys Res Commun 2020;529:596-602.

Novo E, Bocca C, Foglia B, et al. Liver fibrogenesis: un update on established and emerging basic concepts. Arch Biochem Biophys 2020;689:108445.

Wan W, Liu J, Yang B, et al. Modulation of platelet-derived microparticles to adhesion and motility of human rheumatoid arthritis fibroblast like synoviocytes. PLoS One 2017;12:e0181003.

Choi JH, Park SE, Kim SJ, et al. Kaempferol inhibits thrombosis and platelet activation. Biochimie 2015;115:177-186.

Nieswandt B, Varga SD, Elvers M. Integrins in platelet activation. J Thromb Haemost 2009;7:206-209.

Henry MN, Peter S, Harald F. Langer. Platelets in inflammation and atherogenesis. Front Immunol 2015;98:1-11.

Ke J, Han Y. Research progress on target of antiplatelet drugs. Chin Pharm (Chin) 2020;31:2551-2556.

Metharom P, Berndt MC, Baker RI, et al. Current state and novel approaches of antiplatelet therapy. Arter Thromb Vasc Biol 2015;35:1327-1338.

Li HW, Ji H, Hu QH. Research progress of purine receptor P2Y in immune inflammation. Pharm Res (Chin) 2019;38:218-224.

Gurbel PA, Jeong YH, Navarese EP, et al. Platelet-mediated thrombosis: from bench to bedside. Circ Res 2016;118:1380-1391.

Gao Y, Yu C, Pi S, et al. The role of P2Y12 receptor in ischemic stroke of atherosclerotic origin. Cell Mol Life Sci 2019;76:341-354.

Fan H, Chen S, Yuan X, et al. Structural basis for ligand recognition of the human thromboxane A2 receptor. Nat Chem Biol 2019;15:27-33.

Writing Group of Chinese Expert Consensus on Application of Aspirin in Primary Prevention of Cardiovascular Diseases(2019). Chinese expert consensus on application of aspirin in primary prevention of cardiovasc disease (2019). Chin Video J Cardiol (Chin) 2019;2:e1-e9.

Lordan R, Tsoupras A, Zabetakis I, et al. Forty years since the structural elucidation of latelet-activating factor(PAF): historical, current, and future research perspectives.Molecules 2019;24:4414.

Reiner B, Wang W, Liu J, et al. Platelet-activating factor attenuation of long-term potentiation in rat hippocampal slices via protein tyrosine kinase signaling. Neurosci Lett 2016;615:83-87.

Wilson SJ, Iamat FA, Wang Z, et al. PAR4 (proteaseactivated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation. Arterioscler Thromb Vasc Biol 2018;38:448-456.

Zhou WJ, Li JL, Zhou QM, et al. Ginsenoside Rb1 pretreatment attenuates myocardial ischemia by reducing calcium/calmodulin-dependent protein kinase Ⅱ-medicated calcium release. World J Tradit Chin Med (Chin) 2020;6:284-294.

Zhong XN. Chinese expert consensus on platelet activating factor receptor antagonist in the treatment of ischemic stroke. Chin J Neuroimmun Neurol (Chin) 2020;27:1-5,8.

Knowles RB, Warner TD. Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy.Pharmacol Ther 2019;193:83-90.

Yeung J, Li W, Holinstat M, et al. Platelet signaling and disease: targeted therapy for thrombosis and other related diseases. Pharmacol Rev 2018;70:526-548.

Schnitzler JG, Hoogeveen RM, Ali L, et al. Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation. Circ Res 2020;126:1346-1359.

Kakal G, Maitree B. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis.Sci World J 2014;2014:781857.

Li L, Chen H, Shen A, et al. Ligustrazine inhibits platelet activation via suppression of the Akt pathway. Int J Mol Med 2019;43:575-582.

Wang P, Yang HY, Wang LP, et al. Heterogeneity of symptoms and signs of coronary heart disease with blood stasis syndrome and its relationship with heredity. Chin J Tradit Chin Med (Chin) 2014;29:2913-2915.

Plé H, Landry P, Benham A, et al. The repertoire and features of human platelet microRNAs. PLoS One 2012;7:e50746.

Gatfield D, Le Martelot G, Vejnar CE, et al. Integration of microRNA miR-122 in hepatic circadian gene expression.Genes Dev 2009;23:1313-1326.

Simon LM, Edelstein LC, Nagalla S, et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood 2014;123:e37-e45.

Li Y, Wang X, Li CY, et al. Exploration of chemical markers using a metabolomics strategy and machine learning to study the different origins of Ixeris denticulata (Houtt.)Stebb. Food Chem 2020;330:127232.

Xie J, Jiang HQ, Li YL, et al. Study on the intervention effects of Pinggan Prescription on spontaneously hypertensive rats based on metabonomic and pharmacodynamic methods.Chin J Integr Med 2019;25:348-353.

Cui Y, Guo H, Kuang HX, et al. Application of metabonomics in the study of TCM syndrome types. Chin J Tradit Chin Med (Chin) 2017;32:672-675.

Lou TY, Ma BB, Li RJ, et al. Metabonomics based study on the changes of platelet metabolites in Danhong Injection.Chin J Tradit Chin Med (Chin) 2021;46:3422-3428.

Ran N. Explore the effect and mechanism of Dazhu Hongjingtian Injection on acute blood stasis based on omics[dissertation]. Changchun: Jilin University;2020.

Zhou HG, Chen HB, Zhou XP, et al. Proteomics is an important technical platform for TCM pathogenesis research.Chin J Integr Tradit Chin West Med (Chin) 2012;32:990-993.

Karwi QG, Jörg AR, Lopaschuk GD. Allosteric,transcriptional and post-translational control of mitochondrial energy metabolism. Biochem J 2019;476:1695-1712.

Burkhart JM, Vaudel M, Gambaryan S, et al. The first comprehensive and quantitative analysis of humanplatelet protein composition allows the comparative analysis of structural andfunctional pathways. Blood 2012;120:e73-e82.

Li XF, Jiang YR, Gao ZY, et al. Screening, identification and functional analysis of platelet differential functional proteins in coronary heart disease with blood stasis syndrome. Chin J Integr Tradit Chin West Med (Chin) 2010;30:467-473.

Liu Y, Yin HJ, Chen KJ. Research on the correlation between platelet gelsolin and blood-stasis syndrome of coronary heart disease. Chin J Integr Med 2011;17:587-592.

Gallego LD, Schneider M, Mittal C, et al. Phase separation directs ubiquitination of gene-body nucleosomes. Nature 2020;7800:592-597.

Beck F, Geiger J, Gambaryan S, et al. Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition.Blood 2017;129:e1-e12.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Correlation of Platelet and Coagulation Function with Blood Stasis Syndrome in Coronary Heart Disease:A Systematic Review and Meta-Analysis^*

Mechanisms of Dangua Recipe in Improving Glycolipid Metabolic Disorders Based on Transcriptomics

Metabonomics: A Useful Tool to Reveal Underlying Relationships between Altered Chinese Medicine Syndromes and Ultrafiltration in Treatment of Heart Failure

Pathological Observation of Blood Stasis Syndrome in Non-diabetic Peripheral Neuropathies: A Retrospective Analysis Based on Nerve Biopsy

Effect and Safety of Hydroxysafflor Yellow A for Injection in Patients with Acute Ischemic Stroke of Blood Stasis Syndrome: A Phase Ⅱ, Multicenter, Randomized, Double-Blind, Multiple-Dose, Active-Controlled Clinical Trial